Advances in the study of programmed cell death protein 1 and its ligand inhibitors in the treatment of late stage HCC
10.3760/cma.j.issn.1007-3418.2019.09.017
- VernacularTitle: 程序性死亡蛋白1及其配体抑制剂在晚期肝癌治疗中的研究进展
- Author:
Zilong XIAO
1
;
Peng WANG
;
Liping LEI
;
Huabang ZHOU
;
Heping HU
Author Information
1. Department of Hepatobiliary Internal Medicine, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China
- Publication Type:Review
- Keywords:
Carcinoma, hepatocellular;
PD-1;
PD-L1;
Immune checkpoints;
Immunotherapy
- From:
Chinese Journal of Hepatology
2019;27(9):732-736
- CountryChina
- Language:Chinese
-
Abstract:
The treatment of late stage hepatocellular carcinoma (HCC) presently remains a great challenge. A very few drugs have been recently approved for clinical use except sorafenib and lenvatinib. After decades of failure and experience with molecular targeted and immunosuppressive therapy, immune checkpoint inhibitors are becoming one of the potentially effective therapies for patients with HCC, whose tumor is in the middle and late stages. Moreover, immune checkpoint is one of the main mechanisms of tumor immune evasion; of which programmed cell death protein 1 and its ligand (PD1/PD-L1) are important immune checkpoint targets, and its related pathway has shown to have an antitumor effect in a variety of solid or hematologic tumors and its inhibitors can effectively exert antitumor immunosuppressive effects. This review summarizes the current role of PD1/PD-L1 inhibitors in the treatment of late stage HCC, and explores the forecasting value of combined therapy strategy for HCC.
